September 2024

Celebrating Disability Pride and the 34th Anniversary of the ADA at the White House

Leave a Comment / Advocacy, Front Page News /

This week, Cure SMA and advocates with SMA celebrated Disability Pride and the 34th Anniversary of the Americans with Disabilities Act (ADA) with a special reception at the White House. The event marked a significant occasion to reflect on the progress made and the challenges that remain in achieving full equality and inclusion for people […]

Celebrating Disability Pride and the 34th Anniversary of the ADA at the White House Read More »

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Leave a Comment / Front Page News, Industry Updates /

The positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA.  Biogen plans to submit for regulatory approval of this investigational dose regimen. Biogen today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA Read More »

Scroll to Top